A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Inclusion Criteria: * At least 18 years of age * Advanced Melanoma * Completely removed melanoma by surgery performed within 13 weeks of randomization * Adequate organ function * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: * Known history or evidence of ocular or uveal melanoma * Known history of hypersensitivity (grade ≥3) to pembrolizumab or its excipients * Known History of auto-immune disease * Received live vaccine ≤30 days before the first study treatment * Prior treatment with anti-PD-1 agents or agent against another stimulatory or co-inhibitory T cell receptor * Active autoimmune disease that has necessitated chronic systemic treatment within 2 years before the first study treatment Other protocol-defined inclusion/exclusion criteria apply